<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1187">
  <stage>Registered</stage>
  <submitdate>27/03/2006</submitdate>
  <approvaldate>6/04/2006</approvaldate>
  <actrnumber>ACTRN12606000125527</actrnumber>
  <trial_identification>
    <studytitle>New Zealand Eplerenone Aortic Stenosis Trial</studytitle>
    <scientifictitle>A randomised double blind placebo controlled trial to investigate the effects of long term treatment with the aldosterone receptor antagonist eplerenone on left ventricular mass and volume with magnetic resonance imaging in asymptomatic aortic stenosis</scientifictitle>
    <utrn />
    <trialacronym>ZEST</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Aortic stenosis</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Eplerenone 25 to 100mg orally daily to onset of symptoms, 3 years or study end.</interventions>
    <comparator>Placebo orally daily to onset of symptoms, 3 years or study end.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in left ventricular mass and volumes measured by magnetic resonance imaging</outcome>
      <timepoint>At baseline and after onset of symptoms, at 3 years or at study end.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in aortic valve area and peak gradient by echocardiography, and left ventricular hypertrophy by electrocardiogram .</outcome>
      <timepoint>Measured at baseline, every 12 months, and after onset of symptoms or at study end.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma levels of B-type natriuretic peptide and C-reactive protein.</outcome>
      <timepoint>Measured at baseline and every 3 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Symptomatic deterioration due to aortic stenosis.</outcome>
      <timepoint>Before study end.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Aortic stenosis with peak velocity across valve by doppler of &gt;3.0m/s, normal left ventricular function by echocardiography, asymptomatic for aortic stenosis.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Known sensitivity to study medication or spironolactone, age &lt; 18 years, previous aortic valve replacement or scheduled aortic valve replacement with 3 months, other significant heart valve disease of &gt; moderate severity, acute coronary syndrome within previous 6 months, signficant co-morbidity, use of potassium sparing diuretics, serum creatinine &gt;0.13mmol/l during screening period, serum potassium &gt;5.0mmol/l during the screening period, likely poor compliance, gastrointestinal disease which may interefer with the absorption, pharmacokinetics or elimination of eplerenone, left ventricular outlfow obstrcution from a cause other than aortic stenosis, contrindication to magnetic resonance imaging, current enrolment in an investigational drug or device trial, pregant or lactating women or potential for conception, or any condition which in the patient's doctors opinion makes participation in the trial not in the best interest of the patient.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>central randomisation by phone/internet</concealment>
    <sequence>Computer generated randomisation with stratifed allocation by site.  Block size(s) have not been disclosed.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>6/06/2003</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>66</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pfizer (Investigator initated trial conducted independently of sponsor)</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>National Heart Foundation of NZ</fundingname>
      <fundingaddress />
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Pfizer</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Charities/Societies/Foundations</sponsortype>
      <sponsorname>National Heart Foundation of New Zealand</sponsorname>
      <sponsoraddress />
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Aortic stenosis desribes a narrowing of the valve which opens to allow blood to be pumped from the heart.  This narrowing increases the work of the heart and because of this heart function often deteriorates.  The aim of this study is to determine whether eplerenone, an aldosterone receptor antagonist which has already been shown to benefit patients with heart failure, can prevent worsening of heart function in patients with moderate or severe aortic stenosis.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Multi-regional Ethics Committee-Auckland City Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>AKL/2001/174</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Multi-regional Ethics Committee-Whangarei Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>AKL/2001/174</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Multi-regional Ethics Committee-Hamilton Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>AKL/2001/174</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Multi-regional Ethics Committee-North Shore Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>AKL/2001/174</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Multi-regional Ethics Committee-Tauranga Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>AKL/2001/174</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Multi-regional Ethics Committee-Hawkes Bay District Health Board</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>AKL/2001/174</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Multi-regional Ethics Committee-Christchurch Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>AKL/2001/174</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ralph A H Stewart</name>
      <address>Green Lane Cardiovascular Service
Cardiology Department
Auckland City Hospital
Private Bag 92 189
Auckland 1030</address>
      <phone>+64 9 6309943 ext. 23668</phone>
      <fax>+64 9 6310711</fax>
      <email>rstewart@adhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ralph A H Stewart</name>
      <address>Green Lane Cardiovascular Service
Cardiology Department
Auckland City Hospital
Private Bag 92 189
Auckland 1030</address>
      <phone>+64 9 6309943 ext. 23668</phone>
      <fax>+64 9 6310711</fax>
      <email>rstewart@adhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>